Howe & Rusling’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Howe & Rusling’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,250	Closed	-$1K	–	907
2019 Q3	$1K	Buy	+1,250	New	+$696	﹤0.01%	826

Howe & Rusling's CELGZ Position: Q4 2019 in Review

Howe & Rusling sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 1,250 shares — an estimated $1K sold.

Howe & Rusling first reported a position in CELGZ in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.

Howe & Rusling reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
Howe & Rusling sold 1,250 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $1K.
Howe & Rusling first reported a position in Celgene Corporation Contingent Value Rights in Q3 2019 and held it in 1 quarter.
Howe & Rusling's Celgene Corporation Contingent Value Rights position peaked at $1K in Q3 2019.
0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.

Based on Howe & Rusling's 13F filing for Q4 2019, filed 5 Feb 2020.